Liraglutide (GLP-1 agonist)

metabolic glycemic

Approved medicine for another condition in 8 of 9 markets tracked; in clinical trials in 1.

1 randomized trial (128 people, 40 weeks). It improved its main endpoint, a blood or epigenetic marker. 2 trials reported no pre-planned main endpoint. 1 other study gave a different intervention (empagliflozin) and is shown for context, not counted.

Doses studied: 1.8 mg; 3 mg; 3 mg/day.

Evidence map

each mark is a study; size shows participants; hover, tap or focus for details

main endpoints improvedno effectworsenedmixedobservationalanother intervention, contextsize not reported

Higher rows are closer to a person taking this. A case that rests only on the lower rows rests on animals or cells.

What each study measured

outlined square: the main (primary) endpoint

Harms reported

human studies

Where it is available

by regulator; select a market for its source

If you are tracking this yourself

measures the human studies used, by how repeatable they are

Repeatability is whether the same person measured twice gets the same number. It is not statistical significance. It informs study or protocol design only, never advice for a person.

What would change this picture

each study's own statement

Trials under way

Every study (8)

T7 Perna 2016 Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study doi:10.1007/s40520-015-0525-y
T6 Pandey 2024 Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial doi:10.1002/jcsm.13445
T6 Kim 2013 Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes doi:10.2337/dc13-0354
T5 Htoo 2022 Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics doi:10.1001/jamanetworkopen.2022.37606
T3 Durak 2023 Liraglutide provides cardioprotection through the recovery of mitochondrial dysfunction and oxidative stress in aging hearts doi:10.1007/s13105-022-00939-9
T3 Zhang 2020 Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation doi:10.18632/aging.202162
T3 Hu 2024 Liraglutide improves sevoflurane-induced postoperative cognitive dysfunction via activating autophagy and inhibiting apoptosis doi:10.18632/aging.205558
T3 Han 2013 Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats doi:10.1016/j.neurobiolaging.2012.04.009